德国尖端集群计划促进创新药物发展的经验及启示

Experience of leading-edge cluster competition promoting the development of innovative drugs in Germany and its enlightenment

德国尖端集群计划对提升创新药物研发水平、加快药物上市进程有显著成效,该计划的核心特征是促进"政产学研"紧密结合协同创新,以高质量的集群管理营造创新友好型环境,并采用国际化路径整合全球创新资源。本文通过深入分析、借鉴德国的成功经验并结合我国具体国情,提出从构建具有战略共识的创新联盟、提升集群管理的规划能力和资源整合能力,以及提高集群的国际创新网络参与度和品牌影响力3个方面完善我国创新药物政策体系建设。

Leading-edge cluster competition(LECC)has a significant impact on improving the capability of R&D of innovative drugs and accelerating the drug approval process in Germany.The characteristic of LECC includes promoting the collaborative innovation tightly,high-level cluster management to create innovative-friendly environment and the international path to integration of global resources.On the basis of deep understanding of German experience and Chinese actual conditions,it is recommended that innovative drug policy system be optimized by establishing strategic alliance with consensus,enhancing the ability of planning and resource integration of cluster management,and improving the participation in international innovation network.